• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

OrganoReady® Colon Organoid

OrganoReady colon organoid in the OrganoPlate 3-lane 64

Designed for seamless integration in your lab, OrganoReady is a ready-to-use platform delivering 64 perfusable colon tubes into your lab. With just 1-2 days of recovery, the tubules are viable with an assay window of at least 10 days, ensuring consistent and reliable results. This adult stem cell-derived model harnesses the physiological relevance of organoids while providing membrane-free apical and basal access to the model. This allows you to make more accurate predictions of drug responses, such as gastrointestinal toxicity events. Additionally, this model enables the study of human intestinal disease processes, such as for example inflammatory bowel disease.

This is the first ready-to-use adult stem cells derived solution offered license free, presenting a cost-effective solution with no hidden fees!

OrganoReady® Colon Organoid features:

  • Perfusable colon organoid tubules
  • Adult stem cell-derived tissue
  • Polarized epithelium
  • Proliferative phenotype

Download the FlyerPreclinical Research

Fully Characterized Intestinal Model

The perfusable colon organoid tubules are developed in the OrganoPlate® 3-lane 64, a platform which enables membrane free culturing of differentiated adults stem cells derived colon organoids. The tissue shows expression of relevant markers like MUC2, Occludin and Villin, demonstrating the mature nature of the intestinal tissue, with the presence of enterocytes, goblet cells and stem cells. The 3D-lumenized structure provide apical (Ezrin) and basolateral (Integrin β4) access to the polarized epithelium. Additionally, the organoid tubules show polarized and modulatable activity of Pgp, inducible CYP3A4 and functional efflux via BCRP.


Speak With an Expert Explore Our Full OrganoReady® Line

 

A perfusable OrganoReady Colon Organoid tubule with accessible apical and basolateral side, stained for tight junction (Occludin, green) and cell nuclei (blue).

Get inspired


An Expert Discussion: Innovative Approaches For Therapy Development Against Inflammatory Bowel Disease

Webinar: Phenotypic Disease Modeling for Inflammation

Brochure: 3D Tissue Models for Toxicity Assessment

Publication: Assessing Gut Epithelial Barrier Impairment From Food Emulsifiers


How to access our OrganoReady Colon Organoid

Services

MIMETAS offers tailored fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds using. Our flexible fee-for-service model allows you to scale your projects according to demand and timelines. Advance your therapeutics portfolio using the OrganoReady Colon Organoid model, providing a variety of optimized assays at scale. Contact our experts to discuss how we can help you with disease modeling, compound safety and DMPK studies.

OrganoReady

MIMETAS offers ready-to-use models shipped to your laboratory with guaranteed performance according to specifications, in a fast and convenient sales transaction with a clear fee structure. The OrganoReady Colon Organoid model allows screening of compounds to de-risk safety liabilities and repurpose backup compounds with mechanistic insight. Receive the model delivered to your lab, complete with all necessary medium to support your safety studies with optimized protocols. Upon arrival, the model is ready to use after 1-2 days of recovery with an assay window of at least 10 days (TEER> 100 Ω*cm2 ).

Contact us

Living innovation

What customers say
'
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform

James Sabry, Global Head
Roche Pharma Partnering

What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "

Cezmi Akdis
Director SIAF
University Zurich

What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.

Philip Hewitt
Head of Early Investigative Toxicology
Merck KGaA

The 'I' in MIMETAS
Chiwan Chiang
Marketing Specialist
'
A day without
laughter is a day wasted.
Read more
What customers say
'
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data

Scientist
From a top pharma

The 'I' in MIMETAS
Jos Joore
CEO
'
We want to
empower research on complex tissue biology.
Read more
What customers say
'
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!

Scientist
From a top pharma

The 'I' in MIMETAS
Nienke Wevers
Senior Scientist
'
Nothing ventured, nothing gained.
Read more
What customers say
'
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.

Scientist
From a top commercial organization

The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be
mandatory to
socialize with colleagues.
Read more
What customers say
'
Organoplates opened avenues that were before considered unreachable

Laura Perin, PhD
Children’s Hospital Los Angeles

The 'I' in MIMETAS
Bas Trietsch
Chief Technology Officer
'
We try to help
each other
as a team.
Read more
The 'I' in MIMETAS
Jacquelien Ten Dam
Chief Financial Officer
'
It always seems impossible until it’s done.
Read more
The 'I' in MIMETAS
Paul Vulto
CEO
'
Leveraging who you are, is the key to making a difference!
Read more
The 'I' in MIMETAS
Tina Thakkar
Associate Director of Sales
'
It is not really
work if you are
having fun.
Read more
The 'I' in MIMETAS
Liis Rannamäe
Laboratory Technician
'
Can be summarized in three words - engaging, playful, and innovative.
Read more
The 'I' in MIMETAS
Mieke Doornbos
Vice President Sales & Marketing
'
Celebrate
good times.
Read more
The 'I' in MIMETAS
Frederik Schavemaker
Product Design Engineer
'
Pioneering, bringing the best solutions
for scientific
discovery.
Read more
The 'I' in Mimetas
Remko van Vught
Vice President Business Development
'
Making
a difference
together.
Read more
The 'I' in MIMETAS
Lenie van den Broek
Director Biology Discovery
'
Dynamic and innovative - each day holds a surprise.
Read more
The 'I' in Mimetas
Arnaud Nicolas
Associate Director TechCore
'
Own your flaws.
Read more
Latest Whitepaper
'
Closing the Translational Gap in Cancer Drug Discovery with Comprehensive Tumor Models

Discover insights from six oncology applications of MIMETAS’ 3D tumor models.


Download the whitepaper

New Webinar
'
Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context


Now available on demand.

Watch it here

Press Release
'
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology

The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

Read the full article here

News Article
'
First Large-scale Phenotypic Screen Using Organ-on-a-Chip

Leveraging a 3D angiogenesis assay, MIMETAS executed a 1537 kinase inhibitor library screen.


Read the article

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all